Several published studies have demonstrated that TCPMs could have an effective impact on the treatment of HHD with respect to alleviation of symptoms; these can be used to treat ventricular premature beats, arrhythmia, and premature ventricular contractions, as well as effectively improve microcirculation and improve myocardial contractility.[14] Pharmacological studies have shown that TCPMs can protect against myocardial mitochondrial peroxidative damage, reduce levels of inflammatory factors (e.g., TNF-a) in myocardial tissue, and inhibit cardiomyocyte apoptosis. The gene discussed is TNF; the disease is cardiac arrhythmia.